ArticleESC heart failure2025
Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWe aim to evaluate the real-world effectiveness and safety of the Carillon Mitral Contour System (CMCS) for indirect annuloplasty in patients with heart failure (HF) and secondary mitral regurgitation (SMR). METHODS AND
resultsThis was a single-centre retrospective study of 204 consecutive patients (age 83 ± 6 years, 68% female, 72% HFrEF) with NYHA class II-IV HF and moderate and moderate-to-severe (grade 2 + or 3+) SMR planned for CMCS implantation between 2021 and 2024. Echocardiographic variables, B-type natriuretic peptide (BNP) and NYHA functional class were routinely assessed prior to the procedure and, in those with a successful implantation, after 3 months. The device was successfully implanted in 201 (98.5%) patients; the remaining 3 had unsuitable coronary sinus anatomy. Procedural complications occurred in 10.4% and included circumflex artery compression requiring percutaneous coronary intervention (9.5%); coronary sinus injury (1.5%); procedural mortality (0%). At 3 months, NYHA class improved by ≥1 category in 94% of patients and 98% achieved NYHA class I or II. MR decreased by ≥1 grade in 91% of patients, with all patients classified as grade 1+ or 2+ post-procedure. Vena contracta width decreased (6.43 ± 0.84 to 3.85 ± 1.19 mm; P < 0.001), and there was a reduction of LA area from 44.4 ± 6.0 to 35.4 ± 5.1 cm
conclusionsIn this single-centre observational cohort study, CMCS implantation success was high, and associated with low complication rates, improvements in symptoms and echocardiographic variables, and clinically relevant reductions in BNP levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.